881 related articles for article (PubMed ID: 17852440)
1. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
Abdelrazik N; Fouda M
Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
3. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
[TBL] [Abstract][Full Text] [Related]
4. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
7. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.
Saag MS; Bowers P; Leitz GJ; Levine AM;
AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1037-45. PubMed ID: 15587490
[TBL] [Abstract][Full Text] [Related]
9. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
Hudis CA; Vogel CL; Gralow JR; Williams D;
Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
11. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
Provenzano R; Garcia-Mayol L; Suchinda P; Von Hartitzsch B; Woollen SB; Zabaneh R; Fink JC;
Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.
Grossman HA; Goon B; Bowers P; Leitz G;
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):368-78. PubMed ID: 14615654
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
Crawford J; Robert F; Perry MC; Belani C; Williams D;
J Thorac Oncol; 2007 Mar; 2(3):210-20. PubMed ID: 17410044
[TBL] [Abstract][Full Text] [Related]
15. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
16. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
17. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.
Ots PM; Pérez AR; Carrizosa CL; Ocaña CV; de Dios Sáez Garrido J; Delgado Pérez JM
Clin Transl Oncol; 2005 Dec; 7(11):486-92. PubMed ID: 16373059
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D
Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
